Introducing a new, high-sensitivity test to detect blood-based biomarkers of mild traumatic brain injury within 12 hours of head trauma, which gives clinicians the power to predict the absence of intracranial lesions in adult patients with suspected mild traumatic brain injury.
A major focus of recent studies into the assessment of traumatic brain injury (TBI) has been the application of biomarkers in identification and clinical management. Evidence suggests that biomarkers can have applications far beyond detecting brain injuries, including: i) determining whether a mild TBI patient presenting in accident and emergency (A&E) requires a computed tomography (CT) scan for identification of intracranial pathology; ii) guiding personalised management and helping direct resources for optimising care; and iii) guiding clinical research of targeted therapies for TBI by providing information about the underlying pathologies of the condition.
Biomarker panel
A new TBI test from Abbott is an immunoassay panel using glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) measurements in the serum or plasma collected within the first 12 hours after injury in mild TBI (ie Glasgow Coma Score [GCS] 13–15) patients aged 18 or older. Quantitative values are provided for both biomarkers alongside a semi-quantitative interpretation of test results.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.